1. Cho MK, Sankar P, Wolpe PR, Godmilow L. Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet. 1999;83:157–63.
2. American College of Surgeons Cancer Programs. National Accreditation Program for Breast Centers: background statement. Available at: http://napbc-breast.org/ . Accessed January 28, 2014.
3. Genetic Evaluation and Management. Standard 2.16. Cancer risk assessment, genetic counseling and genetic testing services are provided or referred. In: 2013 breast center standards manual. National Accreditation Program for Breast Centers. Chicago, IL: American College of Surgeons; 2013. Available at: http://napbc-breast.org/standards/2013standardsmanual.pdf#52 . Accessed January 29, 2014.
4. Cigna medical coverage policy. Effective September 15, 2013. Genetic testing for susceptibility to breast and ovarian cancer (e.g., BRCA1 and BRCA2). Available at: http://www.elsevierbi.com/~/media/Supporting%20Documents/The%20Gray%20Sheet/39/37/mm_0001_coveragepositioncriteria_genetic_testing_for_breast_and_ovarian_cancer.pdf/ . Accessed January 29, 2014.
5. American Society of Clinical Oncology. Policy statement: new Cigna policy on cancer genetic testing poses risks to high quality cancer care. September 6, 2013. Available at: http://www.asco.org/advocacy/new-cigna-policy-cancer-genetic-testing-poses-risks-high-quality-cancer-care/ . Accessed January 29, 2014.